Salubris Pharmaceuticals’ First-in-Class Anti-Tumor Drug SAL008 Accepted by NMPA
China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced that a clinical trial filing...
Clinical trial filings
Biosyngen’s First-in-Class Drug Candidate BRG01 Accepted for IND Review
Biosyngen has announced that its investigational new drug (IND) filing for the first-in-class (FIC) drug...
Gluetacs Therapeutics Files IND for Molecular Glue Degrading Agent in China
Gluetacs Therapeutics has reported filing an Investigational New Drug (IND) application for its first molecular...
Fudan-Zhangjiang’s JAK1 Inhibitor FZJ-003 Gel Enters Phase I Trial for Atopic Dermatitis
China-based Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349, SHA: 688505) announced that a Phase I...
Junshi Biosciences’ JunMaiKang Biosimilar Gets NMPA Approval Filing
China-based Junshi Biosciiences (HKG: 1877, SHA: 688180) has announced that another market approval filing for...
Coherent Biopharma Raises Series B Funds to Advance Bi-XDC Pipeline
Coherent Biopharma Ltd, a Suzhou-based specialist in bispecific-ligand drug conjugates (Bi-XDC), has reportedly raised an...
Grand Pharma’s TLX591-CDx and TLX250-CDx Advance in China with NMPA Review
Grand Pharmaceutical Group Limited (HKG: 0512) announced that the National Medical Products Administration (NMPA) has...
Frontera Therapeutics Raises $160M in Series B to Advance Gene Therapy FT-001
Sino-US gene therapy specialist Frontera Therapeutics has closed a $160 million Series B funding round,...
Biotheus Inc.’s PM1009 Bispecific Antibody Enters Clinical Trial Review for Solid Tumors
China-based Biotheus Inc. announced that its clinical trial filing for PM1009, a bispecific antibody (BsAb)...
Ascletis Pharma Files IND Application for ASC10 with US FDA
China-based Ascletis Pharma Inc. (HKG: 1672) announced that it has filed an Investigational New Drug...
Beijing Tianshi Tongda Raises RMB 140M for Autoimmune Disease Therapies
China-based Beijing Tianshi Tongda Pharmaceuticals Technology Co., Ltd has reportedly raised RMB 140 million (USD...
Huadong Medicine’s Biosimilar Ozempic (Semaglutide) Wins NMPA Clinical Trial Approval
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that a clinical trial filing for its...
Kexing Pharmaceutical’s Oral COVID-19 Drug SHEN26 Accepted for Clinical Trial Review
China-based Kexing Pharmaceutical (SHA: 688136) announced that a clinical trial application for SHEN26, an oral...